Bora Pharmaceuticals increases US footprint with sterile manufacturing facility

Published: 21-Jun-2024

This bolsters Bora's US fill/finish capabilities for sterile injectables

Bora Pharmaceuticals, a generics manufacturing specialist, has entered into an agreement with Emergent BioSolutions to purchase its sterile manufacturing facility in Baltimore-Camden, Maryland.

The strategic purchase is part of Bora’s commercial expansion project, with another recent initiative in this scheme being the acquisition of Minnesota-based Upsher-Smith Laboratories earlier this year.


Expanding sterile injectable manufacturing capabilities 

The move will expand the company’s North American footprint, as well as its sterile product manufacturing capabilities in the Western hemisphere. 

The 87,000 sqft facility provides drug manufacturing services for sterile injectables and commercial aseptic fill/finish services — including lyophilisation and vial & syringe filling.

This acquisition will allow Bora to offer drug substance and drug product capabilities and complement the services of Bora Biologics.

Chairman and CEO of Bora Group, Bobby Sheng said: “This transaction enables us to expand our offering for our biologics customers. We look forward to working with the hugely talented team at the facility and supporting new and existing customers as we grow and develop the facility.” 

You may also like